Publicaciones en colaboración con investigadores/as de Universitat Pompeu Fabra (30)

2022

  1. Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer

    Science Advances, Vol. 8, Núm. 20

  2. mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer

    Molecular Cancer Research, Vol. 20, Núm. 7, pp. 1108-1121

2021

  1. Preclinical and clinical characterization of fibroblast-derived neuregulin-1 on trastuzumab and pertuzumab activity in HER2-positive breast cancer

    Clinical Cancer Research, Vol. 27, Núm. 18, pp. 5096-5108

2020

  1. Autocrine CCL5 effect mediates trastuzumab resistance by ERK pathway activation in HER2-positive breast cancer

    Molecular Cancer Therapeutics, Vol. 19, Núm. 8, pp. 1696-1707

  2. FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease

    Journal of Clinical Investigation, Vol. 130, Núm. 9, pp. 4871-4887

  3. MicroRNA-33b Suppresses Epithelial–Mesenchymal Transition Repressing the MYC–EZH2 Pathway in HER2+ Breast Carcinoma

    Frontiers in Oncology, Vol. 10

  4. The hippo pathway transducers yap1/tead induce acquired resistance to trastuzumab in her2-positive breast cancer

    Cancers, Vol. 12, Núm. 5

  5. Tumor-associated fibroblasts promote HER2-targeted therapy resistance through FGFR2 activation

    Clinical Cancer Research, Vol. 26, Núm. 6, pp. 1432-1448

2019

  1. NK cell infiltrates and HLA class I expression in primary HER2 þ breast cancer predict and uncouple pathological response and disease-free survival

    Clinical Cancer Research, Vol. 25, Núm. 5, pp. 1535-1545

  2. Contribution of trastuzumab to the prognostic improvement of HER2-positive early breast cancer in Spain: An estimation of life years and disease-free life years gained since its approval

    Oncotarget, Vol. 10, Núm. 42, pp. 4321-4332

  3. Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion

    European Journal of Cancer, Vol. 120, pp. 54-64

  4. High numbers of circulating CD57+ NK cells associate with resistance to her2-specific therapeutic antibodies in HER2+ primary breast cancer

    Cancer Immunology Research, Vol. 7, Núm. 8, pp. 1280-1292

  5. The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors

    Scientific Reports, Vol. 9, Núm. 1

2018

  1. MSK1 regulates luminal cell differentiation and metastatic dormancy in ER + breast cancer

    Nature Cell Biology, Vol. 20, Núm. 2, pp. 211-221

  2. Erratum to: MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer (Nature Cell Biology, (2018), 20, 2, (211-221), 10.1038/s41556-017-0021-z)

    Nature Cell Biology

  3. Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy

    Oncotarget, Vol. 9, Núm. 41, pp. 26406-26416

2017

  1. A PAM50-based chemoendocrine score for hormone receptor-positive breast cancer with an intermediate risk of relapse

    Clinical Cancer Research, Vol. 23, Núm. 12, pp. 3035-3044

  2. Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer

    Clinical Cancer Research, Vol. 23, Núm. 22, pp. 7006-7019

  3. The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene

    Scientific Reports, Vol. 7

2016

  1. C-Jun N-terminal kinase inactivation by mitogen-activated protein kinase phosphatase 1 determines resistance to taxanes and anthracyclines in breast cancer

    Molecular Cancer Therapeutics, Vol. 15, Núm. 11, pp. 2780-2790